Abstract
Investments to reduce the spread of antimicrobial resistance (AMR) in the European Union have been made, including efforts to strengthen prudent antimicrobial use. Using segmented regression, we report decreasing and stabilising trends in data reported to the European Surveillance of Antimicrobial Consumption Network and stabilising trends in data reported to the European Antimicrobial Resistance Surveillance Network. Our results could be an early indication of the effect of prioritising AMR on the public health agenda.
Highlights
Citation style for this article: Peñalva Germán, Högberg Liselotte Diaz, Weist Klaus, Vlahović-Palčevski Vera, Heuer Ole, Monnet Dominique L, ESAC-Net study group, EARS-Net study group
Investments to reduce the spread of antimicrobial resistance (AMR) in the European Union have been made, including efforts to strengthen prudent antimicrobial use
Our analysis shows that the increase in AMR in E. coli and K. pneumoniae was most prominent up to 2012/13, after which there is a tendency towards stabilising levels
Summary
Citation style for this article: Peñalva Germán, Högberg Liselotte Diaz, Weist Klaus, Vlahović-Palčevski Vera, Heuer Ole, Monnet Dominique L, ESAC-Net study group, EARS-Net study group. Decreasing and stabilising trends of antimicrobial consumption and resistance in Escherichia coli and Klebsiella pneumoniae in segmented regression analysis, European Union/European Economic Area, 2001 to 2018. We report decreasing and stabilising trends in data reported to the European Surveillance of Antimicrobial. We describe trends in antimicrobial consumption of fluoroquinolones, third-generation cephalosporins and carbapenems between 2001 and 2018 and for AMR in Escherichia coli and Klebsiella pneumoniae. Joinpoint regression analysis of trends: EU/EEA population-weighted mean consumption expressed in DDD per 1000 inhabitants per day, per antimicrobial group and sector, ESAC-Net/ESAC, 2001–2018. For consumption of third-generation cephalosporins in hospital sector (Table 1, Figure 1) and carbapenems in the hospital sector (Table 1, Figure 3), the most recent segments showed stable levels whereas previous segments www.eurosurveillance.org. Consumption of third-generation cephalosporins by sector and third-generation cephalosporin resistance by microorganism, including detected trend segments, EU/
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
